SCHEMBL99029

SCHEMBL99029

COc1ccc(CSc2nc(N3CCOCC3)c3ncn(CC4CO4)c3n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PDE10A Q9Y233 5/20 0.43
CNR2 P34972 2/20 0.41
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TLR9 Q9NR96 4/20 0.40
TLR7 Q9NYK1 3/20 0.40
HTT P42858 2/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PIK3CA P42336 3/20 0.38
PIK3R1 P27986 2/20 0.38
PIK3CD O00329 1/20 0.38
NOS1 P29475 1/20 0.37
HDAC1 Q13547 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16556646 0.91 PDE10A (0.41) ALDH1A1NPSR1PDE10ATSHRTLR7
SCHEMBL98137 0.90 ALDH1A1 (0.49) ALDH1A1NPSR1PDE10ACNR2HPGD
SCHEMBL98344 0.85 ALDH1A1 (0.49) ALDH1A1NPSR1PDE10ACNR2HPGD
SCHEMBL100676 0.85 ALDH1A1 (0.49) ALDH1A1NPSR1PDE10ACNR2HPGD
SCHEMBL98381 0.84 ALDH1A1 (0.54) ALDH1A1NPSR1PDE10AHPGDTSHR
SCHEMBL98136 0.78 PIK3CA (0.43) PDE10ACNR2TLR9TLR7PIK3CA
SCHEMBL98691 0.77 PDE10A (0.55) ALDH1A1NPSR1PDE10AHPGDTSHR
SCHEMBL99966 0.77 ALDH1A1 (0.54) ALDH1A1NPSR1PDE10AHPGDTSHR
SCHEMBL98870 0.76 PIK3CA (0.45) ALDH1A1NPSR1PDE10AHPGDTSHR
SCHEMBL98635 0.75 ALDH1A1 (0.52) ALDH1A1NPSR1PDE10AHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US claimed
EP-2426130-B1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KK (JP) 2015-03-11 EP claimed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US claimed
EP-2426130-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-03-07 EP claimed
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
EP-2426130-B1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KK (JP) 2015-03-11 EP disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed
EP-2426130-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME PNP, TYMP, DPYD ALDH1A1 336/4885NPSR1 2537/4885PDE10A 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.